Nilo Therapeutics

Nilo Therapeutics is a New York-based, preclinical-stage biotechnology company pioneering a differentiated approach to immunomodulation by targeting the neural circuits that regulate systemic inflammation. Building on seminal discoveries from the laboratories of Charles Zuker (Columbia University / HHMI), Ruslan Medzhitov (Yale), and Stephen Liberles (Harvard) that identified vagal neurons regulating systemic immune activation, and led by CEO Kim Seth, the company harnesses the body-brain axis to restore immune homeostasis centrally, moving beyond conventional immunosuppression to treat autoimmune and inflammatory disease. Nilo launched in 2025 with a $101M Series A co-led by DCVC Bio, Lux Capital, and The Column Group, with participation from Alexandria Venture Investments and the Gates Foundation. As a therapeutics company it publishes no public developer API, SDK, or developer portal surface.

Nilo Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Therapeutics, Immunology, and Neuroscience.

🌐 Visit website 📡 Source on GitHub

7.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyTherapeuticsImmunologyNeuroscienceDrug DiscoveryPharmaceuticalsHealthcare

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 7.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/nilo-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 2

The organization behind the API

Website

Website

LinkedIn

Source (apis.yml)

aid: nilo-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/nilo-therapeutics.png
name: Nilo Therapeutics
description: Nilo Therapeutics is a New York-based, preclinical-stage biotechnology company pioneering a differentiated approach
  to immunomodulation by targeting the neural circuits that regulate systemic inflammation. Building on seminal discoveries
  from the laboratories of Charles Zuker (Columbia University / HHMI), Ruslan Medzhitov (Yale), and Stephen Liberles (Harvard)
  that identified vagal neurons regulating systemic immune activation, and led by CEO Kim Seth, the company harnesses the
  body-brain axis to restore immune homeostasis centrally, moving beyond conventional immunosuppression to treat autoimmune
  and inflammatory disease. Nilo launched in 2025 with a $101M Series A co-led by DCVC Bio, Lux Capital, and The Column Group,
  with participation from Alexandria Venture Investments and the Gates Foundation. As a therapeutics company it publishes
  no public developer API, SDK, or developer portal surface.
url: https://raw.githubusercontent.com/api-evangelist/nilo-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- dcvc
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Therapeutics
- Immunology
- Neuroscience
- Drug Discovery
- Pharmaceuticals
- Healthcare
common:
- type: DomainSecurity
  url: security/nilo-therapeutics-domain-security.yml
- type: Website
  url: https://www.nilotx.com/
- type: LinkedIn
  url: https://www.linkedin.com/company/nilo-therapeutics
apis: []
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 1
  pass: local-v1
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io

Nilo Therapeutics

Kin Score

Security Posture 1

Nilo Therapeutics Domain Security

Resources

Access & Security 1

Company 2

Source (apis.yml)